Biomarker analysis in advanced colorectal cancer patients treated with mFOLFOX6 plus bevacizumab or XELOX plus bevacizumab

ABSTRACT: Interventions: mFOLFOX6 + Bevacizumab or XELOX + Bevacizumab Primary outcome(s): Correlation between plasma VEGF-A level and Progression free survival time in CRC patients Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2627798 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR